UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

A minimal physiologically based pharmacokinetic model for high-dose methotrexate

Cancer chemotherapy and pharmacology, 2021-10, Vol.88 (4), p.595-606

2021

Volltextzugriff (PDF)

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

The Lancet (British edition), 2009-10, Vol.374 (9700), p.1512-1520

2009

Volltextzugriff (PDF)

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review

Cancers, 2023-01, Vol.15 (2), p.526

2023

Volltextzugriff (PDF)

Optimal dose and uncertainty estimation for individualized drug administration using pharmacokinetic models

Computers & chemical engineering, 2021-10, Vol.153, p.107421, Article 107421

2021

Volltextzugriff (PDF)

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure

Frontiers in immunology, 2017-02, Vol.8, p.131-131

2017

Volltextzugriff (PDF)

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

British journal of haematology, 2021-05, Vol.193 (3), p.497-505

2021

Volltextzugriff (PDF)

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3903-3910

2015

Volltextzugriff (PDF)

Gamma-delta t-cell lymphomas

European journal of haematology, 2015-03, Vol.94 (3), p.206-218

2015

Volltextzugriff (PDF)

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

British journal of haematology, 2015-03, Vol.168 (5), p.654-662

2015

Volltextzugriff (PDF)

Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma

Expert opinion on therapeutic targets, 2021-09, Vol.25 (9), p.749-760

2021

Volltextzugriff (PDF)

A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

British journal of haematology, 2021-01, Vol.192 (1), p.119-128

2021

Volltextzugriff (PDF)

780 POTENTIAL RELATIONSHIP BETWEEN MITOCHONDRIAL FERRITIN EXPRESSION AND CARDIOTOXICITY IN PATIENTS UNDERGOING ANTHRACYLINE CHEMOTHERAPY

European heart journal supplements, 2022-12, Vol.24 (Supplement_K)

2022

Volltextzugriff (PDF)

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7575-7575

2018

Volltextzugriff (PDF)

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Blood advances, 2020-08, Vol.4 (15), p.3648-3658

2020

Volltextzugriff (PDF)

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy

Hematological oncology, 2013-09, Vol.31 (3), p.143-150

2013

Volltextzugriff (PDF)

Primary Cardiac Lymphoma in an Immunocompetent 71-Year-Old Man

Texas Heart Institute journal, 2015-12, Vol.42 (6), p.561-564

2015

Volltextzugriff (PDF)

Application of a Pharmacokinetic Model to Inform the Optimal Dose for Individualized Drug Administration

Computer Aided Chemical Engineering, 2020, Vol.48, p.709-714

2020

Volltextzugriff (PDF)

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma

Blood advances, 2022-11, Vol.6 (22), p.5811-5820

2022

Volltextzugriff (PDF)

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Blood, 2013-11, Vol.122 (21), p.4365-4365

2013

Volltextzugriff (PDF)

Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate‐Cytarabine Combination

The oncologist (Dayton, Ohio), 2011-03, Vol.16 (3), p.336-341

2011

Volltextzugriff (PDF)

Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8577-8577

2014

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(90)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(61)
Humans
(40)
Biochemistry & Molecular Biology
(18)
Female
(16)
Male
(15)
Middle Aged
(15)
Pharmacology & Pharmacy
(15)
Hematology
(13)
Oncology
(13)
Adult
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Aged
(11)
Biological And Medical Sciences
(11)
Animals
(10)
Lymphoma
(9)
Oxidation-Reduction
(9)
Central Nervous System
(7)
Central Nervous System Neoplasms - Drug Therapy
(7)
Chemistry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A minimal physiologically based pharmacokinetic model for high-dose methotrexate

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review

Optimal dose and uncertainty estimation for individualized drug administration using pharmacokinetic models

Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

Gamma-delta t-cell lymphomas

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma

A dose‐dense short‐term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high‐risk Burkitt lymphoma or high‐grade B‐cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial

780 POTENTIAL RELATIONSHIP BETWEEN MITOCHONDRIAL FERRITIN EXPRESSION AND CARDIOTOXICITY IN PATIENTS UNDERGOING ANTHRACYLINE CHEMOTHERAPY

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy

Primary Cardiac Lymphoma in an Immunocompetent 71-Year-Old Man

Application of a Pharmacokinetic Model to Inform the Optimal Dose for Individualized Drug Administration

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate‐Cytarabine Combination

Feasibility and efficacy of high doses of antimetabolites followed by high-dose sequential chemoimmunotherapy (R-HDS) and autologous stem cell transplant (ASCT) in patients (pts) with systemic B-cell lymphoma (BCL) and central nervous system (CNS) involvement: A multicenter phase II trial

Suchergebnisse filtern